We have a deep knowledge of global market access issues. Many payors are now reluctant to pay for new products, especially if they are more expensive than existing therapies. To overcome this challenge, we work with clients to develop compelling real world evidence in support of their drugs.

We also assist clients with payor negotiations, helping them build trust-based relationships while simultaneously obtaining optimal reimbursement terms.